Mapk9 Protein (Jnk2) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MAPK9 (Mitogen-Activated Protein Kinase 9), also known as JNK2 (c-Jun N-terminal Kinase 2), is a serine/threonine protein kinase that plays central roles in stress signaling, inflammation, cell proliferation, and apoptosis. JNK2 is one of three JNK isoforms (JNK1, JNK2, JNK3) and is widely expressed in most tissues, including the brain. Unlike JNK3, which is neuron-specific, JNK2 is expressed in neurons and glia.
| Property | Value |
|---|---|
| Gene | MAPK9 |
| UniProt ID | Q9Y0S2 |
| Molecular Weight | 48 kDa |
| Length | 424 amino acids |
| Subcellular Localization | Cytoplasm, Nucleus |
| Family | MAPK family, JNK subfamily |
| Aliases | JNK2, JNK2A, SAPK1A |
| Kinase Domain | residues 45-308 |
MAPK9 has multiple isoforms due to alternative splicing:
The JNK2 protein contains:
JNK2 is activated by dual phosphorylation on Thr183 and Tyr185 by upstream MAP2Ks (MKK4/MKK7).
JNK2 responds to various cellular stresses:
The JNK pathway follows:
MAPK9 is expressed in:
In neurons, JNK2 is localized in both cytosolic and nuclear compartments.
JNK2 plays complex roles in AD pathogenesis:
JNK2/3 deficiency protects against Aβ toxicity in mouse models.
JNK2 contributes to PD pathogenesis:
| Strategy | Agent | Status |
|---|---|---|
| JNK inhibitors | SP600125, JNK-IN-8 | Research |
| Peptide inhibitors | TAT-JNK-interacting protein | Preclinical |
| Natural compounds | Curcumin, BDMA | Research |
| Downstream targets | c-Jun, ATF2 | Research |
Challenges: JNK2 has both protective and pathogenic roles; complete inhibition may have adverse effects.
The study of Mapk9 Protein (Jnk2) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Davis RJ. (2000). Signal transduction by the JNK group of MAP kinases. Cell. PMID:10648792
[2] Manning AM, Davis RJ. (2003). Targeting JNK for therapeutic benefit. Nat Rev Drug Discov. PMID:12858587
[3] Pocivavsek A, et al. (2009). JNK activation in Alzheimer disease. J Neurosci Res. PMID:19301434
[4] Ries V, et al. (2016). JNK signaling in Parkinson disease. Neurodegener Dis. PMID:27055123
[5] Centeno C, et al. (2010). Role of JNK in ALS pathogenesis. Brain Res. PMID:19815014